Zacks Investment Research Lowers Vital Therapies Inc (VTL) to Sell

Zacks Investment Research lowered shares of Vital Therapies Inc (NASDAQ:VTL) from a hold rating to a sell rating in a report issued on Saturday morning.

According to Zacks, “Vital Therapies, Inc. is a biotherapeutic company. It is focused on developing a cell-based therapy targeting the treatment of acute liver failure. The Company operates in the United States, Europe, and China. Vital Therapies, Inc. is based in San Diego, California. “

A number of other research firms also recently weighed in on VTL. BTIG Research reissued a hold rating on shares of Vital Therapies in a research report on Friday, March 10th. Canaccord Genuity set a $10.00 target price on shares of Vital Therapies and gave the company a buy rating in a research report on Monday, January 2nd.

Vital Therapies (NASDAQ:VTL) traded down 1.39% during mid-day trading on Friday, hitting $3.55. The company’s stock had a trading volume of 50,655 shares. Vital Therapies has a 52-week low of $3.50 and a 52-week high of $9.25. The firm has a 50 day moving average of $4.07 and a 200-day moving average of $4.91. The firm’s market cap is $114.11 million.

Vital Therapies (NASDAQ:VTL) last issued its quarterly earnings data on Tuesday, March 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.36) by $0.01. During the same period last year, the company earned ($0.34) EPS. On average, equities research analysts expect that Vital Therapies will post ($1.51) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.chaffeybreeze.com/2017/04/21/vital-therapies-inc-vtl-cut-to-sell-at-zacks-investment-research-updated-updated.html.

In related news, Director Muneer A. Satter acquired 3,750,000 shares of the stock in a transaction dated Monday, March 27th. The shares were purchased at an average price of $4.00 per share, for a total transaction of $15,000,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 29.88% of the company’s stock.

A number of institutional investors have recently modified their holdings of VTL. State Street Corp boosted its position in shares of Vital Therapies by 6.0% in the fourth quarter. State Street Corp now owns 328,091 shares of the company’s stock worth $1,427,000 after buying an additional 18,645 shares during the last quarter. Sei Investments Co. acquired a new position in shares of Vital Therapies during the third quarter worth approximately $321,000. Finally, Victory Capital Management Inc. acquired a new position in shares of Vital Therapies during the third quarter worth approximately $14,214,000. Institutional investors own 26.68% of the company’s stock.

Vital Therapies Company Profile

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

5 Day Chart for NASDAQ:VTL

Get a free copy of the Zacks research report on Vital Therapies (VTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vital Therapies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply